FGF23 Antibody - #DF3596

(3)   (6)  
製品: FGF23 Antibody
カタログ: DF3596
タンパク質の説明: Rabbit polyclonal antibody to FGF23
アプリケーション: WB IHC IF/ICC
反応性: Human, Mouse, Rat
予測: Horse, Dog
分子量: 27 KD; 28kD(Calculated).
ユニプロット: Q9GZV9
RRID: AB_2835968

類似製品を見る>>

   サイズ 価格 在庫状況
 100ul $280 在庫あり
 200ul $350 在庫あり

リードタイム: 当日配達

For pricing and ordering contact:
お問い合わせ先
関連ダウンロード
MS Report
HPLC Report
MSDS
説明書
COA
プロトコル
WB Handbook
IHC Protocol
IF/ICC Protocol

製品説明

ソース:
Rabbit
アプリケーション:
IF/ICC 1:100-1:500, WB 1:500-1000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

反応性:
Human,Mouse,Rat
予測:
Horse(91%), Dog(100%)
クローナリティ:
Polyclonal
特異性:
FGF23 Antibody detects endogenous levels of total FGF23.
RRID:
AB_2835968
引用形式: Affinity Biosciences Cat# DF3596, RRID:AB_2835968.
コンジュゲート:
Unconjugated.
精製:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
別名:

折りたたみ／展開

ADHR; FGF-23; Fgf23; FGF23_HUMAN; FGFN; Fibroblast growth factor 23; Fibroblast growth factor 23 C-terminal peptide; Fibroblast growth factor 23 precursor; HPDR2; HYPF; Phosphatonin; PHPTC; Tumor derived hypophosphatemia inducing factor; Tumor-derived hypophosphatemia-inducing factor;

免疫原

免疫原:
Uniprot:

Q9GZV9(FGF23_HUMAN) >>Visit HPA database.

遺伝子(ID):
FGF23(8074)
発現特異性:
Q9GZV9 FGF23_HUMAN:

Expressed in osteogenic cells particularly during phases of active bone remodeling. In adult trabecular bone, expressed in osteocytes and flattened bone-lining cells (inactive osteoblasts).

タンパク質配列:
MLGARLRLWVCALCSVCSMSVLRAYPNASPLLGSSWGGLIHLYTATARNSYHLQIHKNGHVDGAPHQTIYSALMIRSEDAGFVVITGVMSRRYLCMDFRGNIFGSHYFDPENCRFQHQTLENGYDVYHSPQYHFLVSLGRAKRAFLPGMNPPPYSQFLSRRNEIPLIHFNTPIPRRHTRSAEDDSERDPLNVLKPRARMTPAPASCSQELPSAEDNSPMASDPLGVVRGGRVNTHAGGTGPEGCRPFAKFI

種類予測

種類予測:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Dog
100
Horse
91
Rabbit
73
Pig
0
Bovine
0
Sheep
0
Xenopus
0
Zebrafish
0
Chicken
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - Q9GZV9 基板として

Site PTM Type Enzyme
Y51 Phosphorylation
Y70 Phosphorylation
S71 Phosphorylation
Y154 Phosphorylation
S155 Phosphorylation
S159 Phosphorylation
T178 O-Glycosylation
S180 Phosphorylation Q8IXL6 (FAM20C)
S207 Phosphorylation
S212 Phosphorylation

研究背景

機能:

Regulator of phosphate homeostasis. Inhibits renal tubular phosphate transport by reducing SLC34A1 levels. Upregulates EGR1 expression in the presence of KL (By similarity). Acts directly on the parathyroid to decrease PTH secretion (By similarity). Regulator of vitamin-D metabolism. Negatively regulates osteoblast differentiation and matrix mineralization.

PTMs:

Following secretion this protein is inactivated by cleavage into a N-terminal fragment and a C-terminal fragment. The processing is effected by proprotein convertases.

O-glycosylated by GALT3. Glycosylation is necessary for secretion; it blocks processing by proprotein convertases when the O-glycan is alpha 2,6-sialylated. Competition between proprotein convertase cleavage and block of cleavage by O-glycosylation determines the level of secreted active FGF23.

細胞の位置付け:

Secreted.
Note: Secretion is dependent on O-glycosylation.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
組織特異性:

Expressed in osteogenic cells particularly during phases of active bone remodeling. In adult trabecular bone, expressed in osteocytes and flattened bone-lining cells (inactive osteoblasts).

サブユニット構造:

Interacts with FGFR1, FGFR2, FGFR3 and FGFR4. Affinity between fibroblast growth factors (FGFs) and their receptors is increased by KL and heparan sulfate glycosaminoglycans that function as coreceptors (By similarity).

タンパク質ファミリー:

Belongs to the heparin-binding growth factors family.

研究領域

· Cellular Processes > Cell motility > Regulation of actin cytoskeleton.   (View pathway)

· Environmental Information Processing > Signal transduction > MAPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Ras signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Rap1 signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway.   (View pathway)

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Melanoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Breast cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Gastric cancer.   (View pathway)

参考文献

1). Osteoporotic bone recovery by a bamboo-structured bioceramic with controlled release of hydroxyapatite nanoparticles. Bioactive Materials, 2022 (PubMed: 35386445) [IF=18.9]

Application: WB    Species: Rat    Sample:

Fig. 3 Effect of nwHA bioceramics on cocultured osteoporotic osteoblasts. (A) First line: CLSM observations of live (green)/dead (red) staining of osteoporotic osteoblasts cocultured with different nwHA (first line); Second line: CLSM observations of the osteoporotic osteoblasts with F-actin stained with Phalloidin-TRITC (red) and nuclei stained with DAPI (blue). (B) Cell viability of osteoporotic osteoblasts cocultured with different nwHA bioceramics at days 1, 3, and 5. (C) Cell area quantification of osteoporotic osteoblasts from different groups on day 5. (D) qRT-PCR analysis for ATP2A2 and FGF23 gene expressions of osteoporotic osteoblasts from different groups on day 5. (E) Western blotting analysis for ATP2A2 and FGF23 protein expressions of osteoporotic osteoblasts from different groups on day 5; All data are reported as mean ± standard error. ANOVA with Tukey's post hoc test
2). FGF23 alleviates neuronal apoptosis and inflammation, and promotes locomotion recovery via activation of PI3K/AKT signalling in spinal cord injury. Experimental and Therapeutic Medicine, 2023 (PubMed: 37383378) [IF=2.7]

Application: WB    Species: Rat    Sample:

Figure 1 Cell apoptosis, FGF23 and PI3K/AKT signalling in H2O2-stimulated primary neurons. (A) Relative mRNA expression levels, (B) representative western blotting images of FGF23 and (C) FGF23/GAPDH level. (D) Semi-quantification of apoptotic rates and (E) representative flow cytometry plots of Annexin V/PI staining. (F) Representative western blotting images and (G) relative protein expression levels of C-caspase3 and Bcl-2. (H) Representative western blotting images and (I) relative expression ratios of p-PI3K/PI3K and p-AKT/AKT. GAPDH was used as a loading control. *P
3). IL-6, IL-1β and TNF-α regulation of the chondrocyte phenotype: a possible mechanism of haemophilic cartilage destruction. Hematology (Amsterdam, Netherlands), 2023 (PubMed: 36799502) [IF=1.9]

Application: WB    Species: Human    Sample: chondrocytes

Figure 2. IL-6, TNF-α and IL-1β upregulated FGF23 and downregulated SOX9 protein expression in HUM-iCell-s018 chondrocyte cells. Chondrocytes were treated with gradient concentrations of IL-6, TNF-α or IL-1β (0, 1, 5, 10 ng/ml) for 24 h and protein expression of FGF23 and SOX9 in chondrocytes was determined by WB (a – e). Data are expressed with mean ± SD; (b – e) *p 

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.